Literature DB >> 10496354

Proteolysis in human breast and colorectal cancer.

E A Garbett1, M W Reed, N J Brown.   

Abstract

Proteolysis occurs when proteinase activity exceeds inhibitor activity. Proteolysis is normally tightly regulated and is involved in cancer invasion and metastasis. The aim of this study was to compare proteolysis in breast and colorectal cancer. Proteinase and inhibitor expression were analysed in paired tumour and normal tissue samples from 43 breast and 24 colorectal cancer patients using substrate zymography, Western blotting and quenched fluorescence substrate hydrolysis. The expression of the latent forms of matrix metalloproteinase-2 (MMP-2), MMP-3 and MMP-9, urokinase plasminogen activator (uPA), tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2 expression were observed in both tumour and normal tissue samples from breast and colorectal tissue; however, expression was greater in the tumour tissue. Expression of active MMP-2 and MMP-9 and the total MMP activity were greater in tumour compared to normal samples in both tissues (P < 0.05). The expression of all proteinases and total MMP activity was greater in colorectal tissue than breast tissue samples. Breast and colorectal cancer demonstrated different proteinase profiles, however proteolysis in both tissues was greater in tumour tissue than normal tissue.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10496354      PMCID: PMC2362855          DOI: 10.1038/sj.bjc.6690689

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  37 in total

1.  Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer.

Authors:  F Jänicke; M Schmitt; H Graeff
Journal:  Semin Thromb Hemost       Date:  1991-07       Impact factor: 4.180

2.  Plasma concentration of matrix metalloproteinase 9 in gastric cancer.

Authors:  A Torii; Y Kodera; K Uesaka; T Hirai; K Yasui; T Morimoto; Y Yamamura; T Kato; T Hayakawa; N Fujimoto; T Kito
Journal:  Br J Surg       Date:  1997-01       Impact factor: 6.939

3.  Classification of peptidases.

Authors:  A J Barrett
Journal:  Methods Enzymol       Date:  1994       Impact factor: 1.600

4.  The interaction of purified rabbit bone collagenase with purified rabbit bone metalloproteinase inhibitor.

Authors:  T E Cawston; G Murphy; E Mercer; W A Galloway; B L Hazleman; J J Reynolds
Journal:  Biochem J       Date:  1983-05-01       Impact factor: 3.857

Review 5.  Matrix-degrading metalloproteinases in tumor progression.

Authors:  L M Matrisian; J Wright; K Newell; J P Witty
Journal:  Princess Takamatsu Symp       Date:  1994

6.  Detection and localization of mRNAs encoding matrix metalloproteinases and their tissue inhibitor in human breast pathology.

Authors:  M Polette; C Clavel; M Cockett; S Girod de Bentzmann; G Murphy; P Birembaut
Journal:  Invasion Metastasis       Date:  1993

7.  Expression of activated gelatinase in human invasive breast carcinoma.

Authors:  P D Brown; R E Bloxidge; E Anderson; A Howell
Journal:  Clin Exp Metastasis       Date:  1993-03       Impact factor: 5.150

8.  Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.

Authors:  C Pyke; P Kristensen; E Ralfkiaer; J Grøndahl-Hansen; J Eriksen; F Blasi; K Danø
Journal:  Am J Pathol       Date:  1991-05       Impact factor: 4.307

Review 9.  MMP-2: expression, activation and inhibition.

Authors:  M L Corcoran; R E Hewitt; D E Kleiner; W G Stetler-Stevenson
Journal:  Enzyme Protein       Date:  1996

10.  Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer.

Authors:  A G Remacle; A Noël; C Duggan; E McDermott; N O'Higgins; J M Foidart; M J Duffy
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

View more
  20 in total

1.  Reduced nonprotein thiols inhibit activation and function of MMP-9: implications for chemoprevention.

Authors:  Ping Pei; Michael P Horan; Russ Hille; Craig F Hemann; Steven P Schwendeman; Susan R Mallery
Journal:  Free Radic Biol Med       Date:  2006-07-15       Impact factor: 7.376

2.  Molecular mechanism about lymphogenous metastasis of hepatocarcinoma cells in mice.

Authors:  L Hou; Y Li; Y H Jia; B Wang; Y Xin; M Y Ling; S Lü
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

3.  Galectin-8 expression decreases in cancer compared with normal and dysplastic human colon tissue and acts significantly on human colon cancer cell migration as a suppressor.

Authors:  N Nagy; Y Bronckart; I Camby; H Legendre; H Lahm; H Kaltner; Y Hadari; P Van Ham; P Yeaton; J-C Pector; Y Zick; I Salmon; A Danguy; R Kiss; H-J Gabius
Journal:  Gut       Date:  2002-03       Impact factor: 23.059

4.  Formulation and characterization of injectable poly(DL-lactide-co-glycolide) implants loaded with N-acetylcysteine, a MMP inhibitor.

Authors:  Kashappa Goud H Desai; Susan R Mallery; Steven P Schwendeman
Journal:  Pharm Res       Date:  2007-09-22       Impact factor: 4.200

5.  Human retinal pigment epithelial lysis of extracellular matrix: functional urokinase plasminogen activator receptor, collagenase, and elastase.

Authors:  Susan G Elner
Journal:  Trans Am Ophthalmol Soc       Date:  2002

6.  Active MMP-2 effectively identifies the presence of colorectal cancer.

Authors:  Mary Jo Murnane; Jinguo Cai; Sania Shuja; David McAneny; Veronica Klepeis; John B Willett
Journal:  Int J Cancer       Date:  2009-12-15       Impact factor: 7.396

Review 7.  Soluble E-cadherin: more than a symptom of disease.

Authors:  Magdalena M Grabowska; Mark L Day
Journal:  Front Biosci (Landmark Ed)       Date:  2012-01-01

8.  Serum matrix metalloproteinase 9 and colorectal neoplasia: a community-based evaluation of a potential diagnostic test.

Authors:  S Wilson; S Damery; D D Stocken; G Dowswell; R Holder; S T Ward; V Redman; M J Wakelam; J James; F D R Hobbs; T Ismail
Journal:  Br J Cancer       Date:  2012-03-20       Impact factor: 7.640

9.  A prospective study to assess the value of MMP-9 in improving the appropriateness of urgent referrals for colorectal cancer.

Authors:  Angela V Ryan; Sue Wilson; Michael J O Wakelam; Sally A Warmington; Janet A Dunn; Richard F D Hobbs; Ashley Martin; Tariq Ismail
Journal:  BMC Cancer       Date:  2006-10-23       Impact factor: 4.430

10.  Assessing the value of matrix metalloproteinase 9 (MMP9) in improving the appropriateness of referrals for colorectal cancer.

Authors:  S Damery; L Nichols; R Holder; S T Ward; S Warmington; S Wilson; M J Wakelam; J James; T Ismail
Journal:  Br J Cancer       Date:  2013-02-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.